phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

Despite a myopic focus on drug spending, roughly 30% of every dollar spent on health care in the United States can be attributed to hospitals. Almost 4 times more is spent on hospitals than on retail prescription medicines annually, and this trend is predicted to continue for the foreseeable future. A new report shows how hospitals are driving up costs.

Finding one: Hospitals are charging 500% of what they paid for medicines, on average. For the 20 medicines that were analyzed, hospitals charged a range of more than 200% to more than 700% what they paid, confirming a trend identified in 2018.

hospital charged bar graph

Finding two: Commercial payers reimbursed hospitals almost 200% what the hospital paid to acquire the medicine. Because patient cost sharing is often based on these markups, this practice is driving up costs for patients. selected teaser image

commercial payers bar graph

Finding three: While this paper did not separately analyze data specific to 340B hospitals, it estimates using publicly available data that 340B hospitals are reimbursed, on average, almost three times the discounted 340B price of a medicine. Nearly 60% of all hospitals in the United States participate in the 340B drug pricing program, and the average markup at 340B hospitals is likely higher because medicines acquired by 340B hospitals are purchased at substantial discounts. As policymakers continue to deliberate on health care costs and affordability, they should factor in the increasing role hospitals play in driving costs for patients and the broader health care system.

Full analysis here.

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

As football season kicks off, hospitals keep scoring on 340B

September 9, 2026

ICYMI: Hospital consolidation is driving up health care costs

August 27, 2026

It's time to modernize 340B: The case for a rebate model

August 19, 2026

ICYMI: Fox business hosts call 340B a ‘Rotten System’ and ‘Cash Cow’ for hospitals

July 23, 2026

340B’s reality: A booming business for hospitals, pharmacies and corporate giants

June 25, 2026

340B’s lack of guardrails lets big hospital systems turn it into an oversight-free revenue stream

June 22, 2026

Private equity's new play? Become a nonprofit to profit off 340B.

June 5, 2026

340B is growing, but it is unclear if Illinois patients benefit

May 27, 2026

Fox Business spotlights hospitals abuse of the 340B program

May 15, 2026

The Wall Street Journal raises new alarms about 340B

May 11, 2026

Hospitals in the hot seat: Congress sharpens focus on 340B, consolidation and rising costs

May 7, 2026

New "Goldmine” ad reveals hospitals hide how they profit from 340B markups

May 6, 2026

A program off track: How 340B drives both hospital consolidation and system gaming

April 27, 2026

Washington Post Editorial Board says 340B has become “corporate welfare”

April 27, 2026

Modernizing 340B using rapid verification: The case for a rebate model 

April 20, 2026

Hospitals drive nearly 80% of the U.S. health spending gap

March 25, 2026

Congress should look under the hood of 340B, hospitals don't want them to

March 19, 2026

340B hospitals buy low and sell high, a new analysis shows

March 12, 2026

New report from Minnesota: 340B is generating billions for big hospitals

March 9, 2026

340B hospital markup scheme is costing states, taxpayers billions

February 25, 2026

Questions mount over 340B program and increased cost to everyone

February 23, 2026

PhRMA Forum 2026 highlights the importance of fostering the next era of American leadership

February 18, 2026

50-state poll says Americans are concerned that hospital markups hurt patients

January 27, 2026

New analysis finds 340B hospitals push patients toward costly care to boost profits

January 21, 2026

Data shows tax-exempt hospital profit-seeking behavior, not drug prices, is driving explosive 340B expansion

January 8, 2026

Big, tax-exempt hospitals are charging cancer patients, employers massive medicine markups

January 5, 2026

340B’s billion-dollar boom: Oversight lags as spending soars

December 19, 2025

New study: 340B rebate model pilot won’t hurt cash flow for providers

December 18, 2025

One thing the Senate can agree on: It’s time to fix 340B

November 25, 2025

Middlemen mark up drug prices and keep discounts meant for you

November 10, 2025

The Administration approves manufacturers’ 340B rebate pilot plans

November 6, 2025

340B abuses are fueling higher Medicare costs, new BRG report shows

October 15, 2025

ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs”

September 23, 2025

340B hospitals use scare tactics to evade accountability

September 16, 2025

Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states

September 15, 2025

CBO: 340B program costs taxpayers, no evidence patients benefit

September 10, 2025

PhRMA stresses importance of 340B Rebate Model Pilot

September 9, 2025

New “Meet Mark” ad exposes how the 340B hospital markup program drives up costs for everyone

September 3, 2025

New study unmasks how big-city hospitals exploit 340B by posing as rural providers

August 21, 2025

Study: 340B hospitals drive up patient drug costs

August 15, 2025

Curbing 340B abuse and rising costs with the rebate model

August 12, 2025

The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid

July 14, 2025

Latest analysis from Ohio exposes growing abuses of the 340B markup program

July 7, 2025

New report finds rampant abuse of the 340B program

June 20, 2025

How the 340B hospital markup program could hurt Michigan patients

June 12, 2025

New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines

May 21, 2025

How the 340B hospital markup program and PBMs drive up costs for U.S. patients

May 16, 2025

Foreign first pricing schemes don’t address why Americans pay more

May 15, 2025

When hospitals have free rein to mark up drug prices, who pays the price?

May 1, 2025

New report finds more abuse of 340B program by hospitals and drug middlemen

March 24, 2025

A closer look at how health care consolidation drives up patient costs, creates barriers to care

March 17, 2025

340B markup program is a hidden tax, increasing costs for employers, straining state and federal budgets

March 5, 2025

New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration

February 13, 2025

Wrapping up the J.P. Morgan Healthcare Conference

January 16, 2025

NYT exposes hospitals, middlemen make millions off a hospital markup program

January 15, 2025

PhRMA CEOs Tee Up Next Week's Health Care Conference

January 11, 2025

New study: Entities that don’t make medicines get half of what is spent on those medicines

January 7, 2025

A new administration poses new opportunities for patient access

December 17, 2024

New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear

November 27, 2024

Michigan hospitals using federal program to markup cost of medicines, gouging patients

November 27, 2024

340B spending is exploding, forcing prices up for patients, employers and government programs

November 13, 2024

Three things to know about 340B contract pharmacies

November 12, 2024

PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity

October 18, 2024

Illegal abuse of 340B hurts us all

October 3, 2024

340B sales go up, free or reduced-cost care offered at hospitals goes down

July 1, 2024

ICYMI: Health care policy should be driven by patients, not politics

June 10, 2024

The hidden bill patients don’t know they are paying

June 3, 2024

340B grows and grows, but patients do not see the savings

May 13, 2024

340B grows and grows, but patients do not see the savings

May 13, 2024

Critics repeat same, misleading narrative on potential “costs” of new medicines

May 7, 2024

Insurance data: PBM reform has no material impact on premiums

April 24, 2024

What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong

April 9, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

PBMs using 340B program to drive profits at patients’ expense

March 28, 2024

Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients

February 7, 2024

What’s the 340B program like in your state?

February 7, 2024

New year, same exploitation of the 340B program

January 25, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

How the 340B program became a PBM giveaway

December 11, 2023

New report adds to questions about nonprofit status of 340B hospitals

November 7, 2023

By the Numbers: 340B continues to climb in profits, dwindle with patient support

September 13, 2023

AARP’s latest misleading report

August 11, 2023

New 340B Mega Guidance

August 3, 2023

read more

August 2, 2023

PhRMA responds to Senate: Today’s 340B program leaves patients behind | PhRMA

July 28, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

New studies add to body of evidence questioning 340B efficacy

July 11, 2023

340B program reaches $100 billion in sales, while patients are left behind

June 14, 2023

Insulin: Key Facts on Access & Affordability

May 10, 2023

4 key facts on medicine prices and spending

May 9, 2023

Three facts about health care spending

April 25, 2023

Nonprofit hospitals fall short on community benefit, studies show

April 24, 2023

Why Congress should prioritize fixing the 340B program

March 2, 2023

What they are saying: Nonprofit hospitals are gaming the system at the expense of patients

February 21, 2023

ICYMI: Cancer death rate continues to decline due to treatment advances

January 25, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

Study finds hepatitis C cure saved Medicaid $15 billion

January 5, 2023

340B program continues to drive shift in care to more expensive hospital settings

December 15, 2022

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

November 21, 2022

New data show how insurers and middlemen shift Rx costs onto patients

November 16, 2022

Three ways 340B is failing vulnerable patients

October 20, 2022

If patients aren’t benefiting from the 340B program, who is?

October 6, 2022

Busting 3 Myths About Copay Coupons

October 5, 2022

New data: The 340B program is driving up costs for patients and our health care system

September 15, 2022

Word of the Month: 340B covered entity

August 29, 2022

Making coupons count for patients at the pharmacy counter

August 25, 2022

By the Numbers: Patients lose when the government sets prices

July 8, 2022

Prescription drug prices are not fueling inflation

July 6, 2022

340B program remains second largest federal drug program, yet little solid evidence of benefits to patient

June 30, 2022

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

June 24, 2022

New research finds gaps in charity care provided by 340B hospitals

June 2, 2022

PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients

May 31, 2022

Report finds PBMs are increasingly restricting patient access to medicines

May 25, 2022

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

May 13, 2022

Annual projections from NHE compared to actual health care spending

May 5, 2022

What’s really happening when it comes to prescription drug costs

April 27, 2022

Analysis: States can help patients save nearly $1,000 annually on their medicines

April 21, 2022

New analysis confirms hospitals markup prices for oncology therapies

April 21, 2022

How standardized plans can improve patients’ access to medicines

April 18, 2022

By the numbers: Contract pharmacy participation in the 340B program

March 31, 2022

Correcting the record: Putting medicine costs and spending in context

March 24, 2022

Sharing rebates can save Americans with diabetes 500 each year and improve adherence

March 16, 2022

Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

March 14, 2022

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

March 11, 2022

If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?

March 8, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

February 8, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”

January 25, 2022

CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

January 21, 2022

New study finds more than half of brand medicine spending goes to the supply chain and others

January 7, 2022

New NHE data show the true picture of health care spending

December 22, 2021

Making medicines more affordable: Preserving safety-net programs like 340B

December 17, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

What is missing in the current drug pricing plan

November 23, 2021

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

November 19, 2021

In the current health care debate, Congress has lost sight of what matters to U.S. voters

November 15, 2021

Fact Check: Do contract pharmacies help patients access 340B medicines? No.

November 2, 2021

New video: Why changes to the 340B program are essential for patients

October 28, 2021

CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018

October 19, 2021

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

October 18, 2021

New poll shows Americans reject Medicare negotiation once they learn more about the policy

October 15, 2021

To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system

October 14, 2021

New analysis adds to research questioning whether 340B is working as Congress intended

October 13, 2021

What is Kaiser Family Foundation up to?

October 12, 2021

Recognizing Hepatitis R&D on World Hepatitis Day

July 28, 2021

340B hospitals among those that provide lowest levels of community benefit across the country

July 27, 2021

New reports shed light on key facts about medicines and affordability

June 8, 2021

How strengthening the biosimilar marketplace benefits patients

May 18, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

West Virginia becomes the first state to lower patient costs by sharing the savings

April 20, 2021

Getting the 340B program back on track in 2021

March 10, 2021

Top five issues voters want addressed in the administration’s first 100 days

February 18, 2021

Insurers shift medicine costs to patients with severe chronic illnesses

February 1, 2021

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

December 17, 2020

Fact Check: How hospitals continue to drive health care spending

December 3, 2020

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

November 19, 2020

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

November 2, 2020

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

October 23, 2020

Survey found insurance premiums grew faster than inflation in 2020

October 20, 2020

Growth in 340B program has not translated to improvements for patients

October 5, 2020

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

August 19, 2020

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

August 12, 2020

Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs

August 6, 2020

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

August 5, 2020

New data show commercially insured patients face increasingly high cost sharing for brand medicines

July 30, 2020

Payers subject 80% of new RA and MS patients to utilization management restrictions

July 22, 2020

ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access

June 1, 2020

New rule makes it harder for patients to lower their out-of-pocket costs

May 20, 2020

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

March 3, 2020

Fact Check: HCCI analysis overstates medicine spending and prices

February 19, 2020

Cancer medicines cost twice as much at hospitals, study finds

January 21, 2020

New GAO report: Some hospitals participating in 340B may not be eligible for the program

January 14, 2020

Nearly 50% of brand medicine spending goes to the supply chain and others

January 9, 2020

New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018

December 6, 2019

More evidence that medicine prices are growing at slowest rate in decades

October 4, 2019

Survey shows out-of-pocket costs top health care concern for voters

October 2, 2019

Four reasons why the radical Pelosi Plan is the wrong approach

September 24, 2019

Hospitals make 9 times more than physicians’ offices on provider-administered medicines

September 10, 2019

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

August 20, 2019

Three things to know about the Part D GAO report

August 16, 2019

Setting the record straight on international reference pricing

July 16, 2019

New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?

July 9, 2019

Study finds hospitals continue to mark up medicines up to 500% of their cost

July 9, 2019

Three reasons why the latest Rx Savings Solutions analysis is misleading

July 2, 2019

"If Washington isn’t careful, we might leave innovation behind"

June 24, 2019

Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals

May 16, 2019

Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence

May 15, 2019

New study finds hospitals continue to push patients to costlier outpatient settings

May 13, 2019

4 Things to know about the IQVIA “Medicine Use and Spending” report

May 9, 2019

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

May 9, 2019

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

April 5, 2019

The PBM story you haven’t heard: Hidden fees quadrupled in two years

March 20, 2019

Health Affairs study misses the mark on medicine costs

January 28, 2019

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list